Pfizer’s Zirabev (biosimilar, bevacizumab) Receives the US FDA’s Approval for Five Types of Cancer

Pfizer’s Zirabev (bevacizumab, biosimilar) Receives the US FDA’s Approval for Five Types of Cancer

Shots:

  • The approval is based on REFLECTIONS B7391003 study results assessing Zirabev vs reference product Avastin, in patients with advanced non-sq NSCLC
  • The study resulted in biosimilarity data, showing clinical equivalence and no clinically meaningful differences with the reference product in patients. Additionally, Zirabev is Pfizer’s second oncology biosimilar following Trazimera (trastuzumab-qyyp)
  • Zirabev (bevacizumab-bvzr) is a mAb inhibits formation of new blood cells (angiogenesis) approved by the US FDA for MCC, unresectable/LA/recurrent or mnon-sq NSCLC, recurrent glioblastoma, mRCC, and persistent, recurrent or metastatic cervical cancer

Click here to read full press release/ article | Ref: Pfizer | Image: The Hans India